Ionis Pharmaceuticals (IONS) EBT Margin (2009 - 2026)

Ionis Pharmaceuticals' EBT Margin history runs 18 years deep, the most recent figure standing at 37.51% for Q1 2026.

• In Q1 2026, EBT Margin rose 7405.0% year-over-year to 37.51%; the TTM figure through Mar 2026 stood at 53.72% (up 1109.0% YoY), while the FY2025 annual figure was 40.39%, up 2494.0% from the prior year.
• EBT Margin was 37.51% for Q1 2026 at Ionis Pharmaceuticals, up from 112.87% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 6176.55% in Q2 2025 to a low of 119.44% in Q1 2024.
• Historically, EBT Margin has averaged 301.28% across 5 years, with a median of 47.53% in 2024.
• The sharpest annual moves came in 2022 and 2025: EBT Margin sank 8045 bps in 2022, then soared 620594 bps in 2025.
• A 5-year view of EBT Margin shows it stood at 29.52% in 2022, then soared by 97 bps to 0.85% in 2023, then tumbled by 5474 bps to 47.53% in 2024, then plunged by 137 bps to 112.87% in 2025, then jumped by 67 bps to 37.51% in 2026.
• The last three EBT Margin figures came in at 37.51% (Q1 2026), 112.87% (Q4 2025), and 81.93% (Q3 2025), per Business Quant data.